Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

This Study is Done in Patients With Plaque Psoriasis and Tests How Well They Tolerate BI 730357 and How Effective it is

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03635099
Recruitment Status : Active, not recruiting
First Posted : August 17, 2018
Last Update Posted : May 5, 2020
Sponsor:
Information provided by (Responsible Party):
Boehringer Ingelheim

Tracking Information
First Submitted Date  ICMJE August 15, 2018
First Posted Date  ICMJE August 17, 2018
Last Update Posted Date May 5, 2020
Actual Study Start Date  ICMJE September 17, 2018
Actual Primary Completion Date October 17, 2019   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: August 15, 2018)
  • Achievement of ≥ 75% reduction from baseline PASI (Psoriasis Area and Severity Index) score (PASI 75) at Week 12 [ Time Frame: Up to Week 12 ]
  • Achievement of a sPGA (Static Physician's Global Assessment) score of clear or almost clear at Week 12 [ Time Frame: Up to Week 12 ]
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: April 14, 2020)
  • Achievement of ≥50% reduction from baseline in PASI (Psoriasis Area and Severity Index) score (PASI50) at Week 12 [ Time Frame: Up to Week 12 ]
  • Achievement of ≥90% reduction from baseline in PASI (Psoriasis Area and Severity Index) score (PASI90) at Week 12 [ Time Frame: Up to Week 12 ]
  • Achievement of 100% reduction from baseline in PASI (Psoriasis Area and Severity Index) score (PASI100) at Week 12 [ Time Frame: Up to Week 12 ]
  • Achievement of sPGA (Static Physician's Global Assessment) clear at Week 12 [ Time Frame: Up to Week 12 ]
  • Achievement of ≥75% reduction from baseline in PASI (Psoriasis Area and Severity Index) score (PASI75) at Week 16, 20, 24 [ Time Frame: Up to Week 24 ]
    dose groups A to D
  • Achievement of an sPGA (Static Physician's Global Assessment) score of clear or almost clear at Week 16, 20, 24 [ Time Frame: Up to Week 24 ]
    dose groups A to D
  • Change from baseline in psoriasis symptoms evaluated using the total score on the PSS (Psoriasis Symptoms Scale) at week 12 [ Time Frame: Up to Week 12 ]
  • Achievement of a Dermatology Life Quality Index (DLQI) score of 0 or 1 at Week 12 [ Time Frame: Up to Week 12 ]
Original Secondary Outcome Measures  ICMJE
 (submitted: August 15, 2018)
  • Achievement of ≥50% reduction from baseline in PASI (Psoriasis Area and Severity Index) score (PASI50) at Week 12 [ Time Frame: Up to Week 12 ]
  • Achievement of ≥90% reduction from baseline in PASI (Psoriasis Area and Severity Index) score (PASI90) at Week 12 [ Time Frame: Up to Week 12 ]
  • Achievement of 100% reduction from baseline in PASI (Psoriasis Area and Severity Index) score (PASI100) at Week 12 [ Time Frame: Up to Week 12 ]
  • Achievement of sPGA (Static Physician's Global Assessment) clear at Week 12 [ Time Frame: Up to Week 12 ]
  • Achievement of ≥75% reduction from baseline in PASI (Psoriasis Area and Severity Index) score (PASI75) at Week 16, 20, 24 [ Time Frame: Up to Week 24 ]
  • Achievement of an sPGA (Static Physician's Global Assessment) score of clear or almost clear at Week 16, 20, 24 [ Time Frame: Up to Week 24 ]
  • Change from baseline in psoriasis symptoms evaluated using the total score on the PSS (Psoriasis Symptoms Scale) at week 12 [ Time Frame: Up to Week 12 ]
  • Achievement of a Dermatology Life Quality Index (DLQI) score of 0 or 1 at Week 12 [ Time Frame: Up to Week 12 ]
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE This Study is Done in Patients With Plaque Psoriasis and Tests How Well They Tolerate BI 730357 and How Effective it is
Official Title  ICMJE Phase II Evaluation of Safety, Tolerability, and Efficacy of BI 730357 in Patients With Moderate-to-severe Plaque Psoriasis
Brief Summary The primary objective is based on Week 12 co-primary endpoints of PASI (Psoriasis Area and Severity Index) 75 and sPGA (Static Physician's Global Assessment) 0/1, and overall safety Secondary objectives of Part 1 are to evaluate the efficacy and safety of BI 730357 through 24 weeks of treatment
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Condition  ICMJE Psoriasis
Intervention  ICMJE
  • Drug: BI 730357
    Film-coated tablet
  • Drug: Placebo
    Film-coated tablet
Study Arms  ICMJE
  • Experimental: Dose group A
    Intervention: Drug: BI 730357
  • Experimental: Dose group B
    Intervention: Drug: BI 730357
  • Experimental: Dose group C
    Intervention: Drug: BI 730357
  • Experimental: Dose group D
    Intervention: Drug: BI 730357
  • Placebo Comparator: Placebo
    Intervention: Drug: Placebo
  • Experimental: Dose group V
    Intervention: Drug: BI 730357
  • Experimental: Dose group U
    Intervention: Drug: BI 730357
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Active, not recruiting
Actual Enrollment  ICMJE
 (submitted: October 1, 2019)
178
Original Estimated Enrollment  ICMJE
 (submitted: August 15, 2018)
180
Estimated Study Completion Date  ICMJE July 20, 2021
Actual Primary Completion Date October 17, 2019   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Male or female patients. Woman Of ChildBearing Potential (WOCBP) must be ready and able to use highly effective methods of birth control per International Conference on Harmonisation (ICH) M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly from date of screening until 4 weeks after last treatment in this trial. A list of contraception methods meeting these criteria is provided in the patient information.
  • Age 18 to 75 years (both inclusive) at screening
  • BMI < 35 kg/m2 at screening
  • Diagnosis of chronic plaque psoriasis (with or without psoriatic arthritis) for at least 6 months before the first administration of study drug. Duration of diagnosis may be reported by the patient
  • Patients must be candidates for systemic PsO therapy.Moderate-to-severe plaque psoriasis:

    • BSA ≥10% and
    • PASI ≥12 and
    • sPGA moderate or severe
  • Signed and dated written informed consent in accordance with ICH-GCP and local legislation prior to admission to the trial

Exclusion Criteria:

  • Nonplaque forms of PsO (including guttate, erythrodermic, or pustular), current druginduced PsO (including a new onset or exacerbation of PsO from, e.g., beta blockers, calcium channel blockers, lithium), active ongoing inflammatory diseases (including but not limited to Inflammatory bowel disease (IBD)) other than PsO that might confound trial evaluations
  • Previous enrolment in this trial or previous exposure to BI 730357.
  • Currently enrolled in another investigational device or drug trial, or is less than 30 days (from randomisation) since ending another investigational device or drug trial(s), or is receiving other investigational treatment(s).
  • Use of

    • any biologic agent within 12 weeks, or
    • any anti IL-23 biologic agent within 24 weeks prior to randomisation, or
    • systemic anti-psoriatic medications or phototherapy within 4 weeks prior to randomisation, or
    • topical anti-psoriasis medications within 2 weeks prior to randomisation
  • Received a live vaccination within 12 weeks prior to randomisation (visit 2), or any plan to receive a live vaccination during the conduct of this trial
  • Patients who must or wish to continue the intake of restricted medications or any drug considered likely to interfere with the safe conduct of the trial
  • Patients not expected to comply with the protocol requirements or not expected to complete the trial as scheduled.
  • Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes the patient an unreliable trial participant or unlikely to complete the trial.
  • Major surgery (major according to the Investigator's assessment) performed within 12 weeks prior to randomisation or planned within 12 months after screening, e.g., hip replacement
  • Women who are pregnant, nursing, or who plan to become pregnant while in the trial
  • Any documented active or suspected malignancy or history of malignancy within 5 years prior to screening, except appropriately treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ carcinoma of uterine cervix
  • Relevant chronic or acute infections including human immunodeficiency virus (HIV), viral hepatitis, candidiasis and tuberculosis. A patient can be re-screened if the patient was treated and is cured from the acute infection.
  • Evidence of a current or previous disease (including known or suspected IBD, cardiovascular disease), or medical finding that in the opinion of the Investigator is clinically significant and would make the study participant unreliable to adhere to the protocol or to complete the trial, compromise the safety of the patient, or compromise the quality of the data.
  • Any suicidal ideation, including grade 4 or 5 in the Columbia Suicide Severity Rating Scale (CSSRS) in the past 3 months (i.e., active suicidal thought with intent but without specific plan, or active suicidal thought with plan and intent).
  • Unwillingness to adhere to the rules of UV-light protection
  • Further exclusion criteria apply
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 75 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Canada,   Germany,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03635099
Other Study ID Numbers  ICMJE 1407-0030
2017-004659-21 ( EudraCT Number )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Boehringer Ingelheim
Study Sponsor  ICMJE Boehringer Ingelheim
Collaborators  ICMJE Not Provided
Investigators  ICMJE Not Provided
PRS Account Boehringer Ingelheim
Verification Date May 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP